Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Independence Day
Social Media
Formula 1
Donald Trump
Motorsports
Natural Disasters
Floods
World Cup
Infrastructure
Artificial Intelligence
Immigration
Cryptocurrency
Published • loading... • Updated

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

Summary by Ground News
Six additional weeks of rivaroxaban reduces risk for recurrent venous thromboembolism. In 40 and 43 percent of patients, isolated distal DVT was unprovoked. Proximal DVT or pulmonary embolism occurred in 3 and 4% of patients.

1 Articles

All
Left
Center
1
Right
HealthDayHealthDay
Center

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, according to a study published…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

HealthDay broke the news in on Wednesday, November 30, 2022.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Boone, North Carolina icon

Boone, North Carolina

News
For You
SearchBlindspotLocal